SelectQuote, Inc. Bottom Line Drops In Q2

SelectQuote reported Q2 GAAP net income of $51.17 million, or $0.26 per share, down from $53.24 million, or $0.30 per share a year earlier, while revenue increased 11.6% to $537.10 million from $481.06 million. The quarter reflects solid top-line growth alongside modest compression in profitability on a per-share basis, a mixed result that is unlikely to be market-moving without accompanying forward guidance or other catalysts.

Analysis

Market structure: SelectQuote (SLQT) shows healthy topline expansion (+11.6% YoY to $537.1M) while GAAP EPS fell from $0.30 to $0.26, implying ~155 bps net‑margin compression (11.07%→9.52%). Winners include digital insurance distributors able to monetize scale; losers are high‑CAC entrants and legacy brokers facing pricing pressure if SLQT sustains lower commissions to gain share. Expect pricing power to be mixed: revenue growth gives SLQT optionality to raise CAC or invest in retention, but near‑term margins will cap free cash flow until efficiency gains emerge.

Risk assessment: Key tail risks are regulatory moves (CMS/Medicare compensation caps) and a sustained increase in acquisition cost that would push margins below 8% (profit <~$43M on current revenue). Timeline: immediate (days) — muted stock reaction; short (1–3 quarters) — margin recovery or further compression; long (2–5 years) — network scale or digital disintermediation decides winner. Hidden dependencies: SLQT’s economics likely rely on third‑party lead quality and carrier commission structures; a carrier commission pullback is a second‑order earnings lever.

Trade implications: Tactical: size a restrained long in SLQT (2–3% portfolio) to capture upside from revenue momentum but hedge downside with 3‑month 7% OTM puts or a collar; add to position only if next quarter non‑GAAP operating margin >10.5% or revenue growth remains >8% QoQ. Pair trade: go long SLQT vs short KIE (SPDR S&P Insurance ETF) 1:1 to express distribution outperformance while hedging sector beta. If EPS misses guidance by >8% next quarter, trim long to 0.5% and consider short SLQT (1%) into the miss.

Contrarian angles: The market may overweight the EPS dip and underprice SLQT’s scalable revenue base — if SLQT can restore margins to ~11% within two quarters, upside is >20% from current levels implied by peers. Historical parallel: insurtech rollouts often show front‑loaded CAC then margin re‑leverage (18–24 months); if management pivots to retention (LTV/CAC >3x) expect re‑rating. Unintended consequence: aggressive cost cuts to hit EPS could slow growth and trigger multiple compression; watch guidance language and CAC/LTV cadence closely.

Key Decisions for Investors

• Establish a 2–3% long position in SLQT (ticker SLQT) to exploit 11.6% YoY revenue growth; hedge with a 3‑month 7% OTM protective put sized 50% of the long to cap downside while allowing upside participation.
• Add to the long only if next quarterly non‑GAAP operating margin ≥10.5% or revenue growth maintains >8% QoQ; if EPS misses consensus by ≥8% on the next print, immediately reduce SLQT exposure to 0.5% and consider initiating a 1% short for 4–8 weeks.
• Implement a pair trade: long SLQT vs short KIE (SPDR S&P Insurance ETF) in equal dollar size (1:1) to capture distribution share gains while neutralizing broad insurance single‑stock beta; rebalance at each earnings cycle (quarterly).
• Monitor CMS/Medicare broker compensation guidance and company CAC/LTV metrics over the next 30–60 days; if regulators signal commission caps or if LTV/CAC falls below 2.5x, exit longs and switch to protective puts or short SLQT.